UTS site search

Dr Philip Haywood


Philip Haywood is a clinician and academic with extensive cross disciplinary experience from medical, policy and economic perspectives.  He worked for over a decade in the emergency department at the Newcastle’s Calvary Mater Hospital.

As an economist Phil has investigated the integration of hospital level cancer registries for NSW Health.  At the OECD he researched how different countries have approached the introduction of new technologies.  In Australia, Phil was involved in producing NHMRC guidelines for lung cancer and economic evaluations.  Phil has been involved in trial design and evaluation of new technologies in health care.

His focus is on producing economic evidence for real world decision making with an emphasis on the introduction of new technologies.  He now serves on the protocol advisory sub-committee for the Medical Services Advisory Committee.  He has acted as a clinical advisor to the CHERE economic evaluation team for a decade.

Phil is also currently undertaking his PhD at CHERE.

Image of Philip Haywood
Research Fellow, Centre for Health Economics Research and Evaluation
Core Member, CHERE - Centre for Health Economics and Research Evaluation
Economics, Medicine and Surgery, Economics
+61 2 9514 9896


Haywood, P., Viney & Haas, M. 2017, 'A model of adaptive reimbursement for sequences of pharmaceuticals in oncology treatment [Conference Presentation]', iHEA Boston World Congress, Boston, USA.
Saing, S., Haywood, P. & Goodall, S. 2016, 'Economic evaluation of contrast-enhanced liver MRI in the characterisation of suspected liver lesions', ISPOR Australia Chapter, Contemporary Economic Modelling: State of the Art, Sydney.
Saing, S., Haywood, P. & Goodall, S. 2016, 'Cost effectiveness of contrast-enhanced liver MRI in the characterisation of suspected liver lesions in patients with colorectal cancer', ISPOR Asia-Pacific Conference, Singapore.
Wong, C., Longden, T., van Gool, K. & Hall, J. 2016, 'Morbidity interactions and the cost of healthcare: an analysis of a largesample administrative dataset of primary care, hospital pharmaceutical and total healthcare costs', 38th Annual Australian Health Economics Society Conference, Perth.
Longden, T., Wong, C.Y., Haywood, P., Hall, J. & van Gool, K. 2016, 'A question of persistence and related health states: an analysis of persistently high healthcare costs in the short term and long term', Australian Health Economics Society Conference, Fremantle, Australia.
Haas, M.R. & Haywood, P. 2015, 'Health economics in the genomics era', Sydney Catalyst International Translational Cancer Research Symposium, Sydney.
Haywood, P. 2015, 'Do we need a new system to price oncology pharmaceuticals?', Cancer Institute NSW Innovations Conference, Sydney.
Pearce, A.M., Haas, M., Viney, R., Pearson, S., Haywood, P. & Ward, R. 2014, 'Rates of chemotherapy adverse event in clinical practice: results from a prospective cohort study', World Cancer Congress, Melbourne.
Haas, M.R., Van Gool, K., de Raad, J., Haywood, P. & Ward, R. 2009, 'The Cost of Administering Chemotherapy', iHEA 7th World Congress, Beijing, China.
Faedo, M., Pearson, S., Bastick, P., Van Gool, K., Haywood, P., Haas, M.R. & Ward, R. 2009, 'Elements of Care Study: Tracking resource utilisation and costs in a cohort of NSW cancer patients', 6th Health Services and Policy Conference 2009, Brisbane.
Haywood, P., de Raad, J., Van Gool, K., Gallego, G. & Haas, M.R. 2009, 'Estimating the costs of administering chemotherapy', 6th Health Services and Policy Research Conference 2009, Brisbane.
Pearce, A.M., Haas, M.R., Haywood, P., Van Gool, K., Gallego, G., Pearson, S., Faedo, M. & Ward, R. 2009, 'Chemotherapy, adverse events and costs', 6th Health Services and Policy Conference 2009, Brisbane.
Haywood, P., Van Gool, K., Haas, M.R. & Ward, R. 2008, 'A pragmatic approach to economic evaluation in an age of evidence based clinical guideline production', Australian Conference of Health Economists, Adelaide.

Journal articles

Cronin, P.A., Kirkbidge, B., Bang, A., Smith, D., Parkinson, B. & Haywood, P. 2017, 'Long-term health care costs for patients with prostate cancer: A population-wide longitudinal study in New South Wales Australia', Asia Pacific Journal of Clinical Oncology, vol. 13, no. 3, pp. 160-171.
View/Download from: UTS OPUS or Publisher's site
Daniels, B., Lord, S., Kiely, B., Houssami, N., Lu, C., Ward, R., Haywood, P. & Pearson, S. 2017, 'Use and outcomes of targeted therapies in early and metastatic HER2–positive breast cancer in Australia: Protocol detailing observations in a whole of population cohort', BMJ Open, vol. 7:e014439.
View/Download from: Publisher's site
Saing, S., Haywood, P., Duncan, J., Ma, N., Cameron, A. & Goodall, S. 2017, 'Cost-effective imaging for resectability of liver lesions in colorectal cancer: An economic decision model', ANZ Journal of Surgery.
Pearce, A., Haas, M., Viney, R., Haywood, P., Pearson, S.A., van Gool, K., Srasuebkul, P. & Ward, R. 2015, 'Can administrative data be used to measure chemotherapy side effects?', Expert review of pharmacoeconomics & outcomes research, vol. 15, no. 2, pp. 215-222.
Many of the issues with using data from clinical trials and observational studies for economic evaluations are highlighted in the case of chemotherapy side effects. We present the results of an observational cohort study using linked administrative data. The chemotherapy side effects identified in the administrative data are compared with patient self-reports of such events. The results of these comparisons are then used to guide a discussion of the issues surrounding the use of administrative data to identify clinical events for the population of economic models. Although the advantages of easy access and generalizability of the results make administrative data an attractive option for populating economic models, this is not always possible because of the limitations of these data.
Ward, R.L., Laaksonen, M.A., van Gool, K., Pearson, S.-.A., Daniels, B., Bastick, P., Norman, R., Hou, C., Haywood, P. & Haas, M. 2015, 'Cost of cancer care for patients undergoing chemotherapy: The Elements of Cancer Care study.', Asia Pac J Clin Oncol, vol. 11, no. 2, pp. 178-186.
View/Download from: Publisher's site
AIM: To determine the monthly treatment costs for each element of cancer care in patients receiving chemotherapy and to apportion the burden of cost by financing agent (Commonwealth, State government, private health insurer, patient). METHODS: A cohort of 478 patients (54% breast, 33% colorectal and 13% non-small-cell lung cancer) were recruited from 12 centers representing metropolitan and regional settings in public and private sectors. Primary data were linked to secondary data held in New South Wales state (Admitted Patients and Emergency Department Data) and Commonwealth (Medicare and Pharmaceutical Benefits) databases. The monthly treatment costs of each element of care and the funding agent were calculated from secondary health data. RESULTS: Across all tumor types, the mean monthly treatment cost was $4162 (10%-90% quantiles $1018-$8098; range $2853 [adjuvant colorectal] to $5622 [metastatic lung]), with 54% of this cost borne by Commonwealth government, 26% by private health insurers, 14% by State government and 6% by patients. The mean monthly costs of treating metastatic disease were $1415 greater than those for adjuvant therapy. The mean monthly costs were contributed to by inpatient care ($1657, 40%), chemotherapy prescriptions ($1502, 36%), outpatient care ($452, 11%) and administration of chemotherapy ($364, 9%). CONCLUSION: All four funders have a shared incentive to reduce absolute monthly treatment costs since their proportional contribution is relatively constant for most tumor types and stages. There are opportunities to reduce cancer care costs by minimizing the risk of inpatient hospital admissions that arise from chemotherapy administration and by recognizing incentives for cost-shifting.
Pearce, A.M., Van Gool, K., Haywood, P. & Haas, M.R. 2014, 'Delays in access to affordable medicines: putting policy into perspective - Authors' response', Australian Health Review, vol. 38, no. 1, pp. 16-17.
Haywood, P., de Raad, J., Van Gool, K., Haas, M.R., Gallego, G., Pearson, S., Faedo, M. & Ward, R.L. 2012, 'Title:Chemotherapy administration: modelling the costs of alternative protocols..', Pharmacoeconomics, vol. 30, no. 12, pp. 1173-1186.
View/Download from: UTS OPUS or Publisher's site
Pearce, A.M., Van Gool, K., Haywood, P. & Haas, M.R. 2012, 'Delays in access to affordable medicines: putting policy into perspective', Australian Health Review, vol. 36, no. 4, pp. 412-418.
View/Download from: UTS OPUS or Publisher's site
To save costs, the Australian Government recently deferred approval of seven new medicines recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) for up to 7 months.Objectives: The aim of this research is to examine the timelines of PBAC applications following approval by the Therapeutic Goods Administration (TGA), allowing the recent Cabinet delays to be considered in the context of the overall medicines approval process. Methods. All new chemical entities and products for new indications approved in 2004 by the Australian Drug Evaluation Committee (ADEC) were identified. Outcomes of PBAC meetings from 2004 to 2010 were then searched to identify if and when these products were reviewed by PBAC. Results: ADEC recommended 63 eligible products for registration in 2004. Of the 113 submissions made to PBAC for these products, 66 were successful. Only 43% of the products were submitted to PBAC within 2 years, with an average 17-month delay from TGA approval of a product to consideration by the PBAC. Conclusions: Cabinet decisions to defer listing of new medicines delays access to new treatments. This occurred in addition to other longer delays, earlier in the approval process for medicines, resulting in a significant impact on the overall timeliness of listing.
de Raad, J., Van Gool, K., Haas, M.R., Haywood, P., Faedo, M., Gallego, G., Pearson, S. & Ward, R. 2010, 'Nursing takes time: Workload associated with administering cancer protocols', Clinical Journal of Oncology Nursing, vol. 14, no. 6, pp. 735-741.
View/Download from: UTS OPUS or Publisher's site
New medicines and therapeutic combinations are tested and marketed every year. Healthcare decision makers have to make explicit choices about adopting new treatments and deal with the resource consequences of their choices. The aim of this article is to examine the nursing workload of administering alternative chemotherapy protocols as a driver of costs. Data collection (focus groups with chemotherapy nurses and a survey of nurse unit managers) was conducted to ascertain the time required to undertake chemotherapy-related tasks and the sources of variability in six chemotherapy centers in New South Wales, Australia. Four task types (patient education, patient assessment, administration, and patient communication) were identified as being associated with administering chemotherapy. On average, patient education required 48 minutes during the first visit and 18.5 minutes thereafter, patient assessment took 20.3 minutes, administration averaged 23 minutes, and patient communication required 24.2 minutes. Each center treated an average of 14 patients per day. Each patient received 3.3 hours of staff time (1.7 hours of direct contact time and 1.6 hours of noncontact time). The result of this research will allow healthcare decision makers and evaluators to predict the amount of nursing time required to administer chemotherapy based on the characteristics of a wide range of chemotherapy protocols.
Anderson, R., Haywood, P., Usherwood, T., Haas, M.R. & Hall, J.P. 2005, 'Alternatives to for-profit corporatisation: The view from general practice', Australian Journal of Primary Health, vol. 11, no. 2, pp. 78-86.
View/Download from: UTS OPUS
Bridges, J.F. & Haywood, P. 2003, 'Theory versus empiricism in health economics: as analysis of the past 20 years', European Journal of Health Economics, vol. 4, no. 2, pp. 90-95.
View/Download from: UTS OPUS or Publisher's site
Van Gool, K., Lancsar, E., Viney, R.C., Hall, J.P. & Haywood, P. 2002, 'Diagnosis and prognosis of Australia's health information for evidence based policy', Journal of Health Services Research & Policy, vol. 7, no. 1, pp. 40-45.
View/Download from: UTS OPUS or Publisher's site
Richardson, M., Quiggin, J., Qiu, L.D., Haywood, P., Peacock, A., Cornish, S., Hamilton, G., Adam, C.M., Cavoli, T. & Thornton, S.R. 2002, 'Reviews', The Economic Record, vol. 78, pp. 232-247.
Gibson, P., Powell, H., Coughlan, J., Wilson, A., Abramson, M., Haywood, P., Bauman, A., Hensley, M. & Walters, E. 2002, 'Self-management education and regular practitioner review for adults with asthma', Cochrane Database of Systematic Reviews, no. Issue 3.
View/Download from: Publisher's site


De Abreu Lourenco, R., Haywood, P., Parkinson, B., van Gool, K. & Viney, R. CHERE 2015, The economic implications of a genomically guided approach to cancer: A report by the Centre for Health Economics Research and Evaluation for the Cancer Council, Sydney.
This report examines how genomically based approaches may also alter the way that new technologies are funded and adopted in the health care system. In particular, how they challenge the routine pathways by which technologies are diffused into routine practice. The report also focuses on how genomically guided technologies challenge current coverage decisions. It examines the economic evidence-base for assessing the cost and benefits of such technologies. In doing so, the report highlights the current limitations in this field of research as identified through a systematic review of recommendations made by Australian policy-makers, as well as through a review of the literature. This analysis is then used to develop a framework for economic evaluations with special reference to genomically based technologies. Finally, the report also identifies a number of key policy challenges for the efficient diffusion of genomically guided cancer care into the Australian health care system.
Pollicino, C., Haywood, P. & Hall, J.P. CHERE 2003, Economic evaluation of the proposed surgical scheme at Auburn Hospital: Final report, CHERE Project Report No 19, Sydney.
Viney, R.C., Lowin, A., Pollicino, C., Haywood, P. & Fulham, M.J. CHERE 2002, Review of Positron Emission Tomography at Royal Prince Alfred Hospital, CHERE Project Report No 18, Sydney.